Professional Seasonal Analysis for Trading

CERo Therapeutics Holdings, Inc. - Common Stock (CERO)

Seasonality Analysis

Stocks 5 Years Analyzed

CERo Therapeutics Holdings, Inc. - Common Stock Annual Seasonality Statistics

-144.32%
Avg Annual Return
45.4%
Avg Monthly Win Rate
1/12
Positive Months
5
Years Analyzed

CERo Therapeutics Holdings, Inc. - Common Stock Monthly Seasonality Performance

Month Avg Return Win Rate Strength
January -18.19%
40%
Weak
February -24.02%
20%
Very Weak
March -10.47%
60%
Weak
April -6.20%
60%
Weak
May -21.22%
25%
Very Weak
June -14.64%
75%
Weak
July -14.91%
25%
Very Weak
August -5.64%
50%
Weak
September -12.43%
50%
Weak
October WORST -28.60%
50%
Weak
November BEST 25.92%
50%
Weak
December -13.90%
40%
Weak

CERo Therapeutics Holdings, Inc. - Common Stock 2026 vs Historical Pattern

Current Position
2.78
Historical Avg Position
24.07
Deviation
-21.29
Performance
Significantly Below Average

CERo Therapeutics Holdings, Inc. - Common Stock Interactive Seasonality Chart

Interactive Seasonality Chart

Unlock the full interactive seasonality chart for CERO with overlay patterns, custom date ranges, and more.

Create Free Account

CERo Therapeutics Holdings, Inc. - Common Stock Pattern Scanner

Pattern Scanner

Discover recurring patterns, anomalies, and statistically frequent setups.

Create Free Account

CERo Therapeutics Holdings, Inc. - Common Stock Seasonal Historical Performance

Historical Performance

See historical average returns for CERO across multiple timeframes.

Create Free Account

About CERo Therapeutics Holdings, Inc. - Common Stock (CERO) Seasonality

CERo Therapeutics Holdings, Inc. - Common Stock (CERO) has been analyzed using 5 years of historical data to identify seasonal patterns. Classified under Stocks, CERo Therapeutics Holdings, Inc. - Common Stock shows distinct seasonal tendencies based on historical data.

The strongest month for CERo Therapeutics Holdings, Inc. - Common Stock is historically November, with an average return of 25.92% and a win rate of 50%. Conversely, October tends to be the weakest month, averaging -28.60% return.

Looking at the full calendar year, CERo Therapeutics Holdings, Inc. - Common Stock has an average annual return of -144.32% with an overall monthly win rate of 45.4%. Out of 12 months, 1 typically show positive average returns.

The seasonal pattern for CERo Therapeutics Holdings, Inc. - Common Stock has a consistency score of 24.2 (Poor), based on 6 years of data. Higher consistency means the seasonal pattern has been more reliable across different market conditions.

CERo Therapeutics Holdings, Inc. - Common Stock Seasonality FAQ

What is the best month to buy CERo Therapeutics Holdings, Inc. - Common Stock (CERO)?

Historically, November has been the best month for CERo Therapeutics Holdings, Inc. - Common Stock, with an average return of 25.92% and a win rate of 50%. However, past performance does not guarantee future results.

What is the worst month for CERo Therapeutics Holdings, Inc. - Common Stock (CERO)?

Based on historical data, October has been the weakest month for CERo Therapeutics Holdings, Inc. - Common Stock, with an average return of -28.60%. This is a historical observation and does not guarantee future results.

How reliable is CERO seasonality data?

The seasonality analysis for CERo Therapeutics Holdings, Inc. - Common Stock is based on 5 years of historical price data. While seasonal patterns can provide useful insights, they should be combined with other forms of analysis. Past patterns do not guarantee future performance.

How can I use CERo Therapeutics Holdings, Inc. - Common Stock seasonality in my trading?

Use CERo Therapeutics Holdings, Inc. - Common Stock (CERO) seasonality as one factor in your analysis. Identify historically strong and weak months, combine with other research methods. SeasOptima provides premium tools including interactive charts, pattern scanning, and historical performance data for deeper analysis.

More Stocks Seasonality Analysis

Statistical information based on historical data. Does not constitute investment advice or recommendation. Past performance does not guarantee future results.